fda ruling glp 1 Hims & Hers stock falls 25% as curtails compounded GLP-1s The FDA has strictly clarified

A 2024 Copenhagen-based trial found that participants who maintained a supervised exercise routine after stopping liraglutide regained significantly less weight than those who relied on the medication alone

Although its clinical development is still in early phases, available evidence from adult populations suggests favorable efficacy and tolerability profiles

But here's the challenge: GLP-1 medications dramatically reduce appetite and portion tolerance

Physicians need to be aware of the adverse side effects of these drugs and are encouraged to share this information with their patients prior to commencing therapy with finasteride or dutasteride